Company: NIVFW
Filing Date: 2025-08-21
Form Type: DRS
Source: 0001213900-25-079301
Chunk: 81

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-21
Form: DRS
Chunk 81
---
 surrogacy or providing
intermediary assistance in surrogacy; and (viii) licensing and approval of the accommodation provided as parts of the services.

<div align='center'>45</div>

NewGenIvf has attempted
to structure its operations to comply with laws, regulations and other requirements applicable to it directly and to its clients and
vendors, but there can be no assurance that its operations will not be challenged or impacted by regulatory authorities or
enforcement initiatives, or that the relevant authorities in each jurisdiction could impose higher standards or requirements, which
NewGenIvf may have difficulty to adhere to, e.g. Medical Facilities Act B.E. 2541 (1998) and Protection of a Child Born by
Medically Assisted Reproductive Technology Act B.E. 2558 (2015) for Thailand jurisdiction, Law on Reproduction Rights and on
Guarantees of Their Realization of July 4, 2015 No. 148, Law on status of medical worker of May 28, 2013 No. 81 and Temporary
Regulation on Procedure of Licensing Private Medical Activity approved by the resolution of government of April 4, 2017 No. 203
for Kyrgyz Republic. NewGenIvf in the future may become involved in governmental investigations, audits, reviews and assessments.
Any determination by a court or agency that NewGenIvf’s solutions or services violate, or cause its clients to violate,
applicable laws, regulations or other requirements could subject it or its clients to civil, criminal, or administrative penalties.
Such a determination also could require it to change or terminate portions of its business, disqualify it from serving clients that
do business with government entities, or cause it to refund some or all of its service fees or otherwise compensate its clients. In
addition, failure to satisfy laws, regulations or other requirements could adversely affect demand for its solutions and could force
it to expend significant capital, research and development and other resources to address the failure. Even an unsuccessful
challenge by regulatory and other authorities or parties could be expensive and time-consuming, could result in loss of business,
exposure to adverse publicity, and injury to its reputation and could adversely affect its ability to retain and attract clients. If
NewGenIvf fails to comply with applicable laws, regulations and other requirements, its business, financial condition and results of
operations could be adversely affected. Such non-compliance could also require significant investment to address and may prove